<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971135</url>
  </required_header>
  <id_info>
    <org_study_id>SAN711-01</org_study_id>
    <nct_id>NCT04971135</nct_id>
  </id_info>
  <brief_title>First-in-human Study of SAN711 in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of SAN711 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saniona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, first-in-human, double-blind, randomized, placebo-controlled, parallel group, single&#xD;
      ascending dose (SAD) and multiple ascending dose (MAD) study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent Adverse Events (TEAEs) [SAD]</measure>
    <time_frame>Initiation of dosing through 96 hours post dosing</time_frame>
    <description>Incidence of TEAEs during SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TEAEs [MAD]</measure>
    <time_frame>Initiation of dosing through 16 days post dosing</time_frame>
    <description>Incidence of TEAEs during MAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events of Special Interest (AESIs) [SAD]</measure>
    <time_frame>Initiation of dosing through 96 hours post dosing</time_frame>
    <description>Incidence of AESIs during SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AESIs [MAD]</measure>
    <time_frame>Initiation of dosing through 16 days post dosing</time_frame>
    <description>Incidence of AESIs during MAD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: Cmax [SAD]</measure>
    <time_frame>Baseline (Predose) through 96 hours post dosing</time_frame>
    <description>Maximum observed plasma concentration at Tmax during SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: Cmax [MAD]</measure>
    <time_frame>Day 1 (Predose) through Day 16</time_frame>
    <description>Maximum observed plasma concentration at Tmax during MAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: Tmax [SAD]</measure>
    <time_frame>Baseline (Predose) through 96 hours post dosing</time_frame>
    <description>Time of maximum observed plasma concentration during SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: Tmax [MAD]</measure>
    <time_frame>Day 1 (Predose) through Day 16</time_frame>
    <description>Time of maximum observed plasma concentration during MAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: t1/2 [SAD]</measure>
    <time_frame>Baseline (Predose) through 96 hours post dosing</time_frame>
    <description>Apparent terminal phase half-life during SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: t1/2 [MAD]</measure>
    <time_frame>Day 1 (Predose) through Day 16</time_frame>
    <description>Apparent terminal phase half-life during MAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: AUC-last [SAD]</measure>
    <time_frame>Baseline (Predose) through 96 hours post dosing</time_frame>
    <description>Area under the plasma concentration time curve from time zero to T-last, the time at which Last measurable plasma concentration (C-last) is observed during SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: AUC-last [MAD]</measure>
    <time_frame>Day 1 (Predose) through Day 16</time_frame>
    <description>Area under the plasma concentration time curve from time zero to T-last, the time at which Last measurable plasma concentration (C-last) is observed during MAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: AUC-inf [SAD]</measure>
    <time_frame>Baseline (Predose) through 96 hours post dosing</time_frame>
    <description>Area under the plasma concentration time curve extrapolated to infinity during SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: AUC-inf [MAD]</measure>
    <time_frame>Day 1 (Predose) through Day 16</time_frame>
    <description>Area under the plasma concentration time curve extrapolated to infinity during MAD</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAN711 (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of SAN711</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAN711 (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of SAN711</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN711</intervention_name>
    <description>SAN711 liquid formulation</description>
    <arm_group_label>SAN711 (MAD)</arm_group_label>
    <arm_group_label>SAN711 (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo (MAD)</arm_group_label>
    <arm_group_label>Placebo (SAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, determined by Screening medical evaluation (medical history, physical&#xD;
             examination, vital signs, safety 12-lead electrocardiogram [ECG], and clinical&#xD;
             laboratory evaluations, including liver and renal function tests which must be within&#xD;
             normal limits)&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5 and 29.9 kg/m2, inclusive at Screening&#xD;
&#xD;
          -  Non-smoker (and no other nicotine use) as determined by history (no nicotine use over&#xD;
             the past 6 months) and by urine cotinine concentration (&lt;500 ng/mL) at the Screening&#xD;
             Visit and admission&#xD;
&#xD;
          -  Female participants must be women of non-childbearing potential (WONCBP); defined as&#xD;
             follows: surgically sterile (ie, had a hysterectomy, or bilateral oophorectomy, or&#xD;
             bilateral salpingectomy â‰¥6 months prior to the first dose of study drug); or&#xD;
             Postmenopausal (no menses) for at least 1 year prior to the first dose of study drug.&#xD;
             Postmenopausal status must be confirmed by FSH testing at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a history or evidence of any clinically significant cardiovascular,&#xD;
             general gastrointestinal, endocrine, hematologic, hepatic, immunological, metabolic,&#xD;
             urologic, pulmonary, neurological, dermatologic, psychiatric, renal, and/or other&#xD;
             major disease or malignancy as judged by the investigator&#xD;
&#xD;
          -  Participant answers &quot;yes&quot; to any of the suicide-related behaviors (actual attempt,&#xD;
             interrupted attempt, aborted attempt, preparatory act or behavior) on the &quot;Suicidal&#xD;
             Behavior&quot; portion of the Columbia Suicide Severity Rating Scale&#xD;
&#xD;
          -  Participant's current alcohol intake exceeds 14 units/week for men and women (1 unit =&#xD;
             half pint of beer, 1 glass of wine, 1 measure of spirits)&#xD;
&#xD;
          -  Participant is unwilling to avoid use of alcohol or alcohol-containing foods,&#xD;
             medications or beverages, within 48 hours prior to check-in Day and until final&#xD;
             discharge Day inclusive&#xD;
&#xD;
          -  Participant is unwilling to avoid consumption of caffeine-containing beverages within&#xD;
             48 hours prior to day of admission until final discharge day&#xD;
&#xD;
          -  Participant has a history of illicit substance use OR a positive urine drug test (eg,&#xD;
             cocaine, amphetamines, methylenedioxymethamphetamine (MDMA), barbiturates, opiates,&#xD;
             benzodiazepines, or cannabinoids) or urine alcohol test at the Screening Visit or&#xD;
             admission&#xD;
&#xD;
          -  Participant has a positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C,&#xD;
             or HBsAg negative/anti-HBc positive/anti-HBs negative, or human immunodeficiency virus&#xD;
             (HIV) 1 and/or -2 antibodies&#xD;
&#xD;
          -  At Screening and Baseline, systolic blood pressure (SBP) greater than 140 or less than&#xD;
             90 mm Hg, or diastolic blood pressure (DBP) greater than 90 or less than 40 mm Hg, in&#xD;
             the supine position, at screening or baseline. Borderline values (ie values that are&#xD;
             within 5 mm Hg for blood pressure or 5 beats/min for heart rate) will be repeated.&#xD;
             Subjects can be included if the repeat value is within range or still borderline, but&#xD;
             deemed not clinically significant by the investigator&#xD;
&#xD;
          -  Corrected QT interval using Fridericia's formula &gt;450 msec for males and &gt;470 msec for&#xD;
             females&#xD;
&#xD;
          -  Resting bradycardia (heart rate [HR] &lt;40 beats per minute [bpm]) or tachycardia (HR&#xD;
             &gt;100 bpm)&#xD;
&#xD;
          -  Personal or family history of congenital long QT syndrome or sudden death&#xD;
&#xD;
          -  Screening or Admission ECG with QRS and/or T wave judged to be unfavorable for a&#xD;
             consistently accurate QT measurement (eg, neuromuscular artifact that cannot be&#xD;
             readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T-&#xD;
             and U-waves, prominent U waves)&#xD;
&#xD;
          -  Evidence of atrial fibrillation, atrial flutter, complete branch block,&#xD;
             Wolf-Parkinson-White Syndrome, or cardiac pacemaker at screening or on admission&#xD;
&#xD;
          -  Receipt of COVID-19 vaccine within 2 weeks prior to baseline or scheduled for&#xD;
             vaccination during the study&#xD;
&#xD;
          -  COVID-19 infection within 90 days of screening or evidence of current COVID-19&#xD;
             infection within the past 4 weeks at screening, between screening and admission, or at&#xD;
             admission&#xD;
&#xD;
          -  If unvaccinated for COVID-19, contact with an individual with COVID-19 infection in&#xD;
             the past 14 days at screening, between screening and admission, or at admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carol Lewis-Cullinan</last_name>
    <phone>1 781 839 9100</phone>
    <email>clinicalstudy@saniona.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Boyce, MD</last_name>
      <phone>020 8961 4130</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Sponsor will consider requests for access to SAN711-01 Study materials following completion of SAN711 Development</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

